Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Safinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 6/20 | 0.92 |
| ▸ | MAOA | P21397 | 3/20 | 0.92 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.92 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Safinamide SCHEMBL1665721 | 1.00 | MAOB (0.92) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL1665414 | 1.00 | MAOB (0.92) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL2938424 | 1.00 | MAOB (0.92) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL29358128 | 1.00 | MAOB (0.92) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL1672446 | 0.99 | MAOB (0.90) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL1672442 | 0.99 | MAOB (0.90) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL6431388 | 0.96 | MAOB (0.88) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL6431392 | 0.96 | MAOB (0.88) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL194169 | 0.96 | MAOB (1.00) | MAOBMAOASCN9A | |
| Safinamide SCHEMBL69350 | 0.96 | MAOB (1.00) | MAOBMAOASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011047767-A1 | NOVEL POLYMORPHIC FORMS OF (S)-2-[-4-(3-FLUORO-BENZYLOXY)-BENZYLAMINO]-PROPIONAMIDE MESYLATE SALT AND PROCESSES OF MANUFACTURING THEREOF | MERCK PATENT GMBH (DE) | 2011-04-28 | — | — | WO | claimed |
| EP-2314569-A1 | Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof | Merck Patent GmbH (DE) | 2011-04-27 | — | — | EP | claimed |
| CN-118265693-A | Process for the preparation of safinamides | 扎克系统公司 | 2024-06-28 | — | — | CN | disclosed |
| CN-109414404-B | Pharmaceutical composition comprising safinamide | 萨宝公司 | 2022-08-02 | — | — | CN | disclosed |
| EP-3257842-B1 | THERAPEUTIC USE OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2020-11-18 | — | — | EP | disclosed |
| CN-111821268-A | Safinamide mesylate orally disintegrating tablet and preparation method thereof | 北京万全德众医药生物技术有限公司 | 2020-10-27 | — | — | CN | disclosed |
| EP-3257842-A1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | Newron Pharmaceuticals S.p.A. (IT) | 2017-12-20 | — | — | EP | disclosed |
| EP-2229351-B1 | PROCESS FOR THE PRODUCTION OF 2-[4-(3- OR 2-FLUOROBENZYLOXY)BENZYLAMINO]PROPANAMIDES WITH HIGH PURITY DEGREE | NEWRON PHARM SPA (IT) | 2017-11-08 | — | — | EP | disclosed |
| CN-105949081-A | New crystal form of safinamide mesylate and preparation method of new crystal form | 成都百裕制药股份有限公司 | 2016-09-21 | — | — | CN | disclosed |
| EP-2474521-B1 | High purity degree 2-[4-(3- and 2-fluorobenzyloxy)benzylamino]propanamides for use as medicaments and pharmaceutical formulations containing them | NEWRON PHARM SPA (IT) | 2016-08-10 | — | — | EP | disclosed |
| EP-2029524-B1 | PROCESS FOR THE PRODUCTION OF 2- [4 - ( 3- AND 2-FLUOROBENZYLOXY) BENZYLAMINO] PROPAN AMIDES | NEWRON PHARM SPA (IT) | 2014-11-26 | — | — | EP | disclosed |
| US-20050026909-A1 | Method of treating lower urinary tract disorders | DYNOGEN, INC. | 2005-02-03 | — | — | US | disclosed |
| US-20050020577-A1 | Method of treating lower urinary tract disorders | DYNOGEN, INC. | 2005-01-27 | — | — | US | disclosed |
| US-6846823-B2 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040248979-A1 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. | 2004-12-09 | — | — | US | disclosed |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-28 | — | — | US | disclosed |
| WO-2004089288-A2 | METHOD OF TREATING LOWER URINARY TRACT DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| US-20040209869-A1 | Method of treating lower urinary tract disorders | DYNOGEN PHARMACEUTICALS, INC. | 2004-10-21 | — | — | US | disclosed |
| WO-2004066987-A2 | USE OF SODIUM CHANNEL MODULATORS FOR TREATING GASTROINTESTINAL TRACT DISORDERS | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248979-A1 | Method of treating lower urinary tract disorders | RYR2, CACNA1S, CACNA1D | MAOB 515/4885MAOA 660/4885SCN9A 1931/4885 |
| US-20040213842-A1 | Methods of treating gastrointestinal tract disorders using sodium channel modulators | SLC10A2, VIPR2, TRPV1 | MAOB 987/4885MAOA 995/4885SCN9A 60/4885 |
| US-20050020577-A1 | Method of treating lower urinary tract disorders | HTR3A, HTR3B, HTR3C | MAOB 9/4885MAOA 15/4885SCN9A 3943/4885 |
| US-20040209869-A1 | Method of treating lower urinary tract disorders | HTR3A, HTR3B, MME | MAOB 8/4885MAOA 13/4885SCN9A 3969/4885 |
| US-20040209960-A1 | Methods of treating lower urinary tract disorders using sodium channell modulators | CACNA1G, CACNA1D, CACNA1B | MAOB 845/4885MAOA 983/4885SCN9A 62/4885 |
| US-20050026909-A1 | Method of treating lower urinary tract disorders | HTR3A, HTR3B, HTR3C | MAOB 9/4885MAOA 15/4885SCN9A 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.